NOVOCURE LTD (NVCR)
JE00BYSS4X48 - Common Stock
Overall NVCR gets a fundamental rating of 2 out of 10. We evaluated NVCR against 192 industry peers in the Health Care Equipment & Supplies industry. NVCR may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, NVCR is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
NVCR had negative earnings in the past year.
In the past year NVCR has reported a negative cash flow from operations.
In the past 5 years NVCR reported 4 times negative net income.
NVCR had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
NVCR has a Return On Assets (-18.07%) which is comparable to the rest of the industry.
The Return On Equity of NVCR (-57.13%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.07% | ||
| ROE | -57.13% | ||
| ROIC | N/A |
ROA(3y)-10.32%
ROA(5y)-6.11%
ROE(3y)-30.77%
ROE(5y)-18.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NVCR's Gross Margin of 74.80% is amongst the best of the industry. NVCR outperforms 84.90% of its industry peers.
In the last couple of years the Gross Margin of NVCR has grown nicely.
NVCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.57%
GM growth 5Y2.01%
2. Health
2.1 Basic Checks
NVCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
NVCR has more shares outstanding than it did 1 year ago.
NVCR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NVCR is higher compared to a year ago.
2.2 Solvency
NVCR has an Altman-Z score of 0.51. This is a bad value and indicates that NVCR is not financially healthy and even has some risk of bankruptcy.
NVCR has a Altman-Z score (0.51) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.57 is on the high side and indicates that NVCR has dependencies on debt financing.
NVCR has a Debt to Equity ratio of 1.57. This is amonst the worse of the industry: NVCR underperforms 84.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.57 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.51 |
ROIC/WACCN/A
WACC8.32%
2.3 Liquidity
NVCR has a Current Ratio of 5.78. This indicates that NVCR is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.78, NVCR is doing good in the industry, outperforming 77.08% of the companies in the same industry.
A Quick Ratio of 5.56 indicates that NVCR has no problem at all paying its short term obligations.
NVCR has a better Quick ratio (5.56) than 81.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.78 | ||
| Quick Ratio | 5.56 |
3. Growth
3.1 Past
The earnings per share for NVCR have decreased strongly by -121.59% in the last year.
NVCR shows a decrease in Revenue. In the last year, the revenue decreased by -5.28%.
NVCR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.47% yearly.
EPS 1Y (TTM)-121.59%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-25%
Revenue 1Y (TTM)-5.28%
Revenue growth 3Y1%
Revenue growth 5Y15.47%
Revenue growth Q2Q4.19%
3.2 Future
Based on estimates for the next years, NVCR will show a small growth in Earnings Per Share. The EPS will grow by 5.58% on average per year.
The Revenue is expected to grow by 10.31% on average over the next years. This is quite good.
EPS Next Y8.09%
EPS Next 2Y2.04%
EPS Next 3Y1.35%
EPS Next 5Y5.58%
Revenue Next Year6.2%
Revenue Next 2Y7.03%
Revenue Next 3Y8.97%
Revenue Next 5Y10.31%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NVCR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVCR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.04%
EPS Next 3Y1.35%
5. Dividend
5.1 Amount
NVCR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NOVOCURE LTD
NASDAQ:NVCR (5/1/2024, 7:13:31 PM)
Premarket: 13.2998 +0.56 (+4.39%)12.74
+0.5 (+4.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.36B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.07% | ||
| ROE | -57.13% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.8% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.57 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.78 | ||
| Quick Ratio | 5.56 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-121.59%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y8.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-5.28%
Revenue growth 3Y1%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y